AstraZeneca plc (AZN) Shares Rating Restated by Jefferies Group LLC

AstraZeneca plc (AZN) Shares Rating Restated by Jefferies Group LLC

AstraZeneca plc (LON:AZN)‘s stock had its “sell” rating reaffirmed by research analysts at Jefferies Group LLC in a report released on Tuesday. They presently have a GBX 3,900 ($50.10) target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target suggests a potential downside of 25.56% from the stock’s previous close.

A number of other equities analysts have also commented on the company. Deutsche Bank AG dropped their price objective on AstraZeneca plc from GBX 5,500 ($70.65) to GBX 5,350 ($68.72) and set a “buy” rating on the stock in a research note on Friday, April 28th. Barclays PLC reiterated an “overweight” rating and issued a GBX 6,000 ($77.07) price objective on shares of AstraZeneca plc in a research note on Monday, March 27th. Goldman Sachs Group Inc set a GBX 3,900 ($50.10) price objective on AstraZeneca plc and gave the stock a “sell” rating in a research note on Friday, February 3rd. Societe Generale reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, March 23rd. Finally, HSBC Holdings plc lowered AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($57.80) price objective on the stock. in a research note on Friday, April 7th. Six equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. AstraZeneca plc has an average rating of “Hold” and a consensus target price of GBX 5,001.80 ($64.25).

Shares of AstraZeneca plc (AZN) traded down 0.50% on Tuesday, reaching GBX 5201.00. The company had a trading volume of 871,278 shares. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company has a 50-day moving average price of GBX 4,853.46 and a 200-day moving average price of GBX 4,592.95. The firm’s market capitalization is GBX 65.84 billion.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:AZN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment